TCRX logo

TScan Therapeutics (TCRX)

Profile

Full Name

TScan Therapeutics, Inc.

Ticker Symbol

TCRX

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

July 16, 2021

Indexes

Not included

Website

http://www.tscan.com

Employees

194

Key Details

Price

$1.36(+4.62%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$2.82M(-86.62% YoY)

Annual EPS

-$1.14(+16.18% YoY)

PE ratio

-

Next earnings date

May 13, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$1.36
TCRX price is $1.36

30-Day Relative Volume

1.40
TCRX 30-day relative volume is 1.40

Price Performance

Price Today change

+4.62%
TCRX price is up +4.62% today

Price YTD change

-55.26%
TCRX price is down -55.26% since January 1st

Price 1-year change

-80.93%
TCRX price is down -80.93% year-on-year

Price 3-year change

-48.29%
TCRX price is down -48.29% over the past 3 years

Price Range

Price All-time high

$14.71
TCRX price is currently -90.75% below its historical high of $14.71

Price 3-year low

$1.02
TCRX price is currently +33.33% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$76.96M
TCRX market capitalization is $76.96 million

Market cap 3-year change

+21.63%
TCRX market capitalization is up +21.63% over the past 3 years

Market cap All-time high

$493.21M
TCRX market capitalization is currently -84.40% below its historical high of $493.21 million

Market cap sector rank

44.74%
TCRX market capitalization is higher than 44.74% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+18.13%
TCRX shares outstanding is up +18.13% year-on-year

Shares Outstanding 3-Year Change

+135.2%
TCRX shares outstanding is up +135.2% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.90
TCRX beta is 0.90

200-day SMA

$4.13
TCRX price is currently -67.04% below its 200-day simple moving average

50-day SMA

$1.75
TCRX price is currently -22.34% below its 50-day simple moving average

RSI

41.61
TCRX 14-day relative strength index is 41.61

Volume

1.40
TCRX 30-day relative volume is 1.40

ATR

$0.15
TCRX average true range is $0.15

10-day Historical Volatility

119.45%
TCRX 10-day historical volatility is 119.45%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$2.82M
TCRX annual revenue is $2.82 million

Revenue Analysts estimate

$6.95M
TCRX annual revenue is currently -59.48% lower than the consensus analysts' forecast

Revenue 1-year change

-86.62%
TCRX annual revenue is down -86.62% year-on-year

Revenue Sector rank

17.77%
TCRX annual revenue is higher than 17.77% of companies in Healthcare sector

EPS

EPS

-$1.14
TCRX annual earnings per share is -$1.14

EPS Analysts estimate

-$1.13
TCRX annual earnings per share is currently +0.93% higher than the consensus analysts' forecast

EPS 1-year change

+16.18%
TCRX annual earnings per share is up +16.18% year-on-year

EPS Sector rank

53.52%
TCRX annual earnings per share is higher than 53.52% of companies in Healthcare sector

Profit

Gross profit

-
TCRX annual gross profit value is unknown

Gross margin

-
TCRX annual gross profit margin value is unknown

Operating profit

-$134.82M
TCRX annual operating income is -$134.82 million

Operating margin

-4787.68%
TCRX annual operating profit margin is -4787.68%

Net income

-$127.50M
TCRX annual net profit is -$127.50 million

Net margin

-4527.66%
TCRX annual net profit margin is -4527.66%

Expenses

Total expenses

$137.64M
TCRX annual total expenses is $137.64 million

Operating expenses

$137.64M
TCRX annual total operating expenses is $137.64 million

Cost of goods sold

-
TCRX annual cost of goods sold value is unknown

Selling, general & administrative expenses

$29.56M
TCRX annual SGA is $29.56 million

Depreciation and amortization

$4.11M
TCRX annual depreciation & amortization is $4.11 million

Interest expense

$3.65M
TCRX annual interest expense is $3.65 million

Income tax

-
TCRX annual income tax value is unknown

EBIT & EBITDA

EBIT

-$123.85M
TCRX annual earnings before interest & taxes is -$123.85 million

EBITDA

-$119.74M
TCRX annual EBITDA is -$119.74 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$371.12M
TCRX annual total assets is $371.12 million

Non current assets

$78.40M
TCRX annual long term assets is $78.40 million

Current assets

$292.72M
TCRX annual total current assets is $292.72 million

Cash and cash equivalents

$178.69M
TCRX annual cash & cash equivalents is $178.69 million

Accounts receivable

-
TCRX annual accounts receivable value is unknown

Inventory

-
TCRX annual inventory value is unknown

Liabilities

Total liabilities

$130.15M
TCRX annual total liabilities is $130.15 million

Long term liabilities

$94.19M
TCRX annual total long term liabilities is $94.19 million

Current liabilities

$35.96M
TCRX annual total current liabilities is $35.96 million

Accounts payable

$4.28M
TCRX annual accounts payable is $4.28 million

Debt

Total debt

$97.38M
TCRX annual total debt is $97.38 million

Total debt 1-year change

+5.35%
TCRX annual total debt is up +5.35% year-on-year

Long term debt

$92.81M
TCRX annual long term debt is $92.81 million

Short term debt

$4.57M
TCRX annual short term debt is $4.57 million

Equity & Capital

Shareholders equity

$240.97M
TCRX annual stockholders equity is $240.97 million

Book value

$240.97M
TCRX annual book value is $240.97 million

Retained earnings

-$375.10M
TCRX annual retained earnings is -$375.10 million

Working capital

$256.77M
TCRX annual working capital is $256.77 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$110.82M
TCRX annual cash flow from operations is -$110.82 million

Cash from operations 1-year change

-80.62%
TCRX annual cash flow from operations is down -80.62% year-on-year

Cash from investing

-$52.61M
TCRX annual cash flow from investing activities is -$52.61 million

Cash from investing 1-year change

+13.41%
TCRX annual cash flow from investing activities is up +13.41% year-on-year

Cash from financing

$208.76M
TCRX annual cash flow from financing activities is $208.76 million

Cash from financing 1-year change

+54.13%
TCRX annual cash flow from financing activities is up +54.13% year-on-year

CAPEX

CAPEX

$3.83M
TCRX annual capital expenditures is $3.83 million

CAPEX 1-year change

+21.58%
TCRX annual capital expenditures is up +21.58% year-on-year

Free Cash Flow

Free cash flow

-$114.65M
TCRX annual free cash flow is -$114.65 million

Free cash flow 1-year change

-77.74%
TCRX annual free cash flow is down -77.74% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
TCRX annual gross profit margin value is unknown

Operating margin

-4787.68%
TCRX annual operating profit margin is -4787.68%

Net margin

-4527.66%
TCRX annual net profit margin is -4527.66%

ROA & ROE

ROA

-39.64%
TCRX annual return on assets is -39.64%

ROE

-65.08%
TCRX annual return on equity is -65.08%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
TCRX price to earnings ratio value is unknown

PE ratio Sector rank

-
TCRX price to earnings ratio is unknown

PB Ratio

PB ratio

0.32
TCRX price to book ratio is 0.32

PB ratio Sector rank

24.2%
TCRX price to book ratio is higher than 24.2% of companies in Healthcare sector

PS Ratio

PS ratio

27.33
TCRX price to sales ratio is 27.33

PS ratio Sector rank

88.85%
TCRX price to sales ratio is higher than 88.85% of companies in Healthcare sector

Enterprise value

Enterprise value

-$4.34M
TCRX enterprise value is -$4.34 million

Enterprise value Sector rank

6.62%
TCRX enterprise value is higher than 6.62% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

0.04
TCRX EV/EBITDA is 0.04

EV/EBITDA Sector rank

65.62%
TCRX EV/EBITDA is higher than 65.62% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

8.14
TCRX annual current ratio is 8.14

Quick ratio

-
TCRX annual quick ratio value is unknown

Leverage

Debt to equity

0.13
TCRX annual debt to equity ratio is 0.13

Interest coverage ratio

-33.90
TCRX annual interest coverage ratio is -33.90

Risk & Stability

Piotroski F-Score

-
TCRX piotroski f-score value is unknown

Altman Z-Score

-1.32
TCRX altman z-score is -1.32

Analyst ratings

Recent major analysts updates

Apr 8, 25 Needham
Buy
Mar 7, 25 Barclays
Overweight
Mar 6, 25 HC Wainwright & Co.
Buy
Mar 5, 25 Needham
Buy
Dec 11, 24 Needham
Buy
Dec 11, 24 HC Wainwright & Co.
Buy
Nov 15, 24 HC Wainwright & Co.
Buy
Nov 12, 24 Needham
Buy
Nov 6, 24 Needham
Buy
Aug 13, 24 Wedbush
Outperform

Institutional Ownership

Similar stocks

ASMB logo
Assembly Biosciences (ASMB)
IFRX logo
InflaRx NV (IFRX)
Alpha Cognition (ACOG)
CRBP logo
Corbus Pharmaceuticals Holdings (CRBP)
XCUR logo
Exicure (XCUR)
IMAB logo
I-Mab (IMAB)
NSPR logo
InspireMD (NSPR)
CARA logo
Cara Therapeutics (CARA)
CRBU logo
Caribou Biosciences (CRBU)
  • What is the ticker symbol for TScan Therapeutics?
  • Does TScan Therapeutics pay dividends?
  • What sector is TScan Therapeutics in?
  • What industry is TScan Therapeutics in?
  • What country is TScan Therapeutics based in?
  • When did TScan Therapeutics go public?
  • Is TScan Therapeutics in the S&P 500?
  • Is TScan Therapeutics in the NASDAQ 100?
  • Is TScan Therapeutics in the Dow Jones?
  • When was TScan Therapeutics's last earnings report?
  • When does TScan Therapeutics report earnings?
  • Should I buy TScan Therapeutics stock now?

What is the ticker symbol for TScan Therapeutics?

The ticker symbol for TScan Therapeutics is NASDAQ:TCRX

Does TScan Therapeutics pay dividends?

No, TScan Therapeutics does not pay dividends

What sector is TScan Therapeutics in?

TScan Therapeutics is in the Healthcare sector

What industry is TScan Therapeutics in?

TScan Therapeutics is in the Biotechnology industry

What country is TScan Therapeutics based in?

TScan Therapeutics is headquartered in United States

When did TScan Therapeutics go public?

TScan Therapeutics's initial public offering (IPO) was on July 16, 2021

Is TScan Therapeutics in the S&P 500?

No, TScan Therapeutics is not included in the S&P 500 index

Is TScan Therapeutics in the NASDAQ 100?

No, TScan Therapeutics is not included in the NASDAQ 100 index

Is TScan Therapeutics in the Dow Jones?

No, TScan Therapeutics is not included in the Dow Jones index

When was TScan Therapeutics's last earnings report?

TScan Therapeutics's most recent earnings report was on Mar 5, 2025

When does TScan Therapeutics report earnings?

The next expected earnings date for TScan Therapeutics is May 13, 2025

Should I buy TScan Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page